Originally published In Press as doi:10.1074/jbc.M202287200 on May 7, 2002
J. Biol. Chem., Vol. 277, Issue 29, 26547-26552, July 19, 2002
A Functional Green Fluorescent Protein-tagged
Erythropoietin Receptor Despite Physical Separation of JAK2 Binding
Site and Tyrosine Residues*
Robin
Ketteler
§,
Achim C.
Heinrich
¶,
Julia K.
Offe
,
Verena
Becker
,
Jacob
Cohen
,
Drorit
Neumann
**, and
Ursula
Klingmüller
§**
From the
Max-Planck-Institute of Immunobiology, 79108 Freiburg, Germany and
Sackler-Faculty of Medicine, Department of
Cell Biology and Histology, Tel-Aviv University,
69978 Ramat-Aviv, Israel
Received for publication, March 8, 2002, and in revised form, May 2, 2002
 |
ABSTRACT |
Signaling through hematopoietic cytokine
receptors such as the erythropoietin receptor (EpoR) depends on the
activation of a receptor-bound Janus kinase (JAK) and tyrosine
phosphorylation of the cytoplasmic domain. To visualize the EpoR and
elucidate structural requirements coordinating signal transduction, we
probed the EpoR by inserting the green fluorescent protein (GFP) at
various positions. We show that insertion of GFP in proximity to the
transmembrane domain, either in the extracellular or the cytoplasmic
domain, results in EpoR-GFP receptors incompetent to elicit biological responses in a factor-dependent cell line or in erythroid
progenitor cells. Surprisingly, a receptor harboring GFP insertion in
the middle of the cytoplasmic domain, and thereby separating the JAK2 binding site from the tyrosine residues, is capable of supporting signal transduction in response to ligand binding. Comparable with the
wild type EpoR, but more efficient than a C-terminal EpoR-GFP fusion,
this chimeric receptor promotes the maturation of erythroid progenitor
cells and is localized in punctated endosome-like structures. We
conclude that the extracellular, transmembrane, and membrane-proximal
segment of the cytoplasmic domain form a rigid structural entity
whose precise orientation is essential for the initiation of signal
transduction, whereas the cytoplasmic domain possesses flexibility in
adopting an activated conformation.
 |
INTRODUCTION |
Ligand binding to membrane-spanning receptors supports signaling
networks within cells. The specific structural requirements that enable
conversion of ligand binding to the extracellular domain to an
activated conformation of the cytoplasmic domain are poorly understood.
Hematopoietic cytokine receptors share common features in the
extracellular domain such as four spaced cysteines near the N terminus
and a Trp-Ser-X-Trp-Ser (WSXWS) motif located
proximal to the cell membrane (for a review, see Refs. 1 and 2). The
cytoplasmic domain of hematopoietic cytokine receptors lack intrinsic
enzymatic activity and therefore require recruitment of cytoplasmic
kinases to promote signal transduction. A simple prototype of the
hematopoietic cytokine receptor family is the erythropoietin receptor
(EpoR)1 that is essential for
the development of mature erythrocytes. Crystallographic evidence
suggests that in the absence of ligand, the EpoR exists as a preformed
dimer in an open scissors-like conformation (3). Upon ligand binding, a
conformational switch facilitated by self-interaction of the
transmembrane domains is induced, permitting the activation of an
intracellular signal transduction cascade (4). This process is
supported by a conserved hydrophobic motif localized in the cytoplasmic
juxtamembrane domain of the EpoR (5). A continuous stretch of residues
in the membrane-proximal domain of the EpoR mediates binding of the
Janus kinase JAK2 and ensures transport of the EpoR from the
endoplasmic reticulum to the cell surface (6). The precise orientation
of critical residues in the juxtamembrane motif is essential for JAK2
activation. Negative inhibitory molecules including the suppressor of
cytokine signaling family of proteins (7) and tyrosine phosphatases
such as SHP-1 (8), PTP-1B (9), and CD45 (10) tightly regulate JAK2. In
addition, JAK2 is involved in activation of signal transducer and
activator of transcription protein 1 (STAT1) and STAT3 by the EpoR, as
shown by the use of the JAK2 inhibitor AG490 (11). The cytoplasmic
domain of the activated EpoR mediates the recruitment of secondary
signaling molecules including the lipid kinase phosphoinositide 3-kinase (12, 13) and activation of STATs that promote signal transmission from the cell surface to the nucleus. STAT1, STAT3, and
STAT5 are involved in EpoR signal transduction (11, 14-16). Docking of
the tyrosine phosphatase SHP-1 leads to termination of signal
transduction (8, 17). Signaling pathways activated in response to
ligand binding to the EpoR have been studied in detail, but it is
unresolved how activation of JAK2 is communicated to phosphorylation of
the eight tyrosine residues localized in the membrane-distal
cytoplasmic domain.
Here we present a set of EpoR-GFP fusion proteins that are 1)
ER-retained and signaling-incompetent, 2) surface-expressed but
signaling-incompetent, and 3) surface-expressed and
signaling-competent. Our analysis shows that the cytoplasmic domain of
the EpoR can tolerate a large insertion separating the JAK2-activating
segment from the respective tyrosine residues and yet coordinate
biological responses supporting proliferation and differentiation of
erythroid progenitor cells.
 |
EXPERIMENTAL PROCEDURES |
Constructs--
Primers used are summarized in Table
I. Thermostabilizing amino acid exchanges
V163A, I167T, and S175G were introduced into the cDNA of enhanced
green fluorescent protein (CLONTECH, Palo Alto, CA)
by overlap extension PCR using as general 5'-primer primer number
1 that introduces a BglII restriction site and as general 3'-primer primer 2 encoding an EcoRI restriction
site. V163A and I167T were introduced concomitantly using the primers 3-U and 3-L. Using the resulting cDNA as a template, S175G was introduced with the primers 4-U and 4-L. The EpoR-GFP receptors were
generated by overlap extension PCR including the following steps. To
generate EpoR-GFP1, first a shortened EpoR was established harboring a
BamHI restriction site at amino acid position 224 in the
EpoR without altering the amino acid sequence. The shortened EpoR
fragment flanked by BclI/SalI (5') and
BglII/EcoRI (3') restriction sites was generated
using primers 5, 6-L, 6-U, and 7 and was cloned into the
BamHI and EcoRI restriction sites in the
retroviral vector pBABE (pBABE-EpoR-BamHI). Second, an
in-frame fusion of the EpoR extracellular domain and GFP was
established using primers 5, 8-L, 8-U, and 9. The joined fragment was
subcloned via the SalI and BamHI in
pBABE-EpoR-BamHI. Finally, inserting the EpoR
BglII/EcoRI restriction fragment into
pBABE-EpoR-BamHI, resulting in pBABE-EpoR-GFP1, completed
the EpoR cDNA.
To generate EpoR-GFP2, an EpoR subfragment (amino acids 1-304)
encompassing the EpoR extracellular domain and transmembrane (TM)
domain was produced using primers 5 and 10. The PCR fragment was
digested with BclI and cloned into pBABE cut with
BamHI and SalI (blunt), resulting in
pBABE-EpoR-NotI. By PCR amplification, BglII (5')
and NotI (3') restriction sites were introduced at the
respective ends of the GFP cDNA using primers 11 and 12. The PCR
fragment was subcloned via BglII and NotI
in pBABE-NotI. The EpoR cDNA was completed by PCR
amplification using primers 13 and 14 and inserting the PCR fragment
NotI and EcoRI in pBABE-EpoR-NotI, resulting in pBABE-EpoR-GFP2. EpoR-GFP3 bearing GFP inserted at amino
acid position 336 in the EpoR cDNA was generated by using primers
15, 16-L, 16-U, and 17 and subcloned via BglII and
SphI into the respective restriction sites in pBS-EpoR that
harbors the EpoR cDNA inserted into BamHI and
EcoRI in pBluescript II KS (Stratagene).
EpoR-GFP4 harbors GFP fused to the C terminus of the EpoR and was
generated by introducing NotI and EcoRI
restriction sites at the 3'-end of the EpoR cDNA. The EpoR
cytoplasmic domain was amplified using primers 13 and 18 and subcloned
via BamHI and EcoRI into
pBABE-EpoR-NotI, resulting in
pBABE-EpoR-NotIcyto. NotI and
EcoRI restriction sites flanking the GFP cDNA were
amplified by PCR with primers 19 and 20 and inserted via
NotI and EcoRI in
pBABE-EpoR-NotIcyto.
The resulting EpoR-GFP cDNAs were verified by automated sequencing
and inserted via SalI and EcoRI digestion into
pMOWS (18).
The HA tag was inserted into wild type EpoR by excising the
HA-containing fragment with EcoRI and BamHI from
pMX-HA-EpoR-IRES-GFP (kindly provided by Dr. Stefan Constantinescu,
Ludwig Institute for Cancer Research, Brussels, Belgium) and subcloning
it into the EcoRI and PacI restriction sites of
pMOWS-EpoR, yielding pMOWS-HA-EpoR. HA-EpoR-GFP1 and HA-EpoR-GFP2 were
generated by subcloning the PmlI and BamHI
fragment from pMOWS-EpoR-GFP1 or pMOWS-EpoR-GFP2 into the corresponding
sites of pMOWS-HA-EpoR.
Cell Lines and Cultures--
The retroviral vectors were
transiently transfected in Phoenix-Eco cells by calcium phosphate
precipitation (18) and visualized after 24 h or used for the
production of transducing supernatants as described (18). Transducing
supernatants were applied to introduce the cDNA for the EpoR or
EpoR-GFP chimera into the interleukin-3-dependent pro-B
cell line BaF3 and fetal liver cells.
Pools of BaF3 cells expressing the wild type EpoR or the EpoR-GFP
chimera were selected in 1.5 µg/ml puromycin (Sigma) 48 h after
transduction. Cell pools expressing comparable amounts of the receptors
were identified by immunoblotting and used for further experiments. The
selected cells were maintained in RPMI 1640 medium (Invitrogen)
supplemented with 10% fetal calf serum (Invitrogen) and 10%
WEHI-conditioned medium in the presence of 1.5 µg/ml puromycin.
Fetal liver cells derived from 12.5-day-old embryos from
EpoR
/
mice (19) were prepared and transduced as
described (18). The transduced cells were plated in 0.8%
methylcellulose (StemCell Technologies, Vancouver, Canada) supplemented
with 4 units/ml Epo (Cilag-Jansen, Bad Homburg, Germany).
Colony-forming unit-erythroid (CFU-E) colony formation was monitored by
benzidine staining of hemoglobinized cells. To ensure comparable
transduction rates, GFP expression was assessed by
fluorescence-activated cell sorting analysis (FACScan; Becton
Dickinson, Palo Alto, CA) in transduced fetal liver cells of wild type
mice after 20 h of cultivation in Iscove's modified
Eagle's medium supplemented with Epo.
Surface Binding--
Three independent pools of BaF3 cells
expressing the wild type EpoR or EpoR-GFP chimera were analyzed by
saturation binding of 125I-labeled Epo as described (20).
Surface expression of HA-tagged EpoR was evaluated by flow cytometry
(FACScan). BaF3 cells selected in puromycin were incubated with rat
anti-HA (Roche Molecular Biochemicals) as primary antibody and anti-rat
IgG coupled to Cy5 (Dianova, Hamburg, Germany) as secondary antibody
and analyzed for green and red fluorescence by flow cytometry.
Immunoprecipitation and Immunoblotting--
BaF3 cells
expressing the wild type EpoR or the EpoR-GFP chimera were starved for
3 h in RPMI with 1 mg/ml bovine serum albumin and then stimulated
for 5 min at 37 °C with 50 units/ml Epo. Detergent lysates
equivalent to 1 × 107 cells were prepared using
Nonidet P-40 buffer as described (8) and subjected to
immunoprecipitation using anti-EpoR (Santa Cruz Biotechnology, Inc.,
Santa Cruz, CA), anti-JAK2 (Upstate Biotechnology, Inc., Lake Placid,
NY), anti-STAT5b (Santa Cruz Biotechnology), anti-p85 subunit of
phosphatidylinositol 3-kinase (kindly provided by Dr. Lewis Cantley,
Harvard Medical School, Boston, MA), and anti-SHP1 (Santa Cruz
Biotechnology) antiserum. The immunoprecipitates were eluted, resolved
by 15% SDS-PAGE, and transferred to a nitrocellulose membrane.
Detection by immunoblotting was performed with an anti-phosphotyrosine monoclonal antibody (4G10, Upstate Biotechnology, Inc., Lake Placid, NY) followed by enhanced chemoluminescence (Amersham Biosciences). The
blots were stripped and reprobed with anti-EpoR, anti-STAT5b, anti-JAK2, anti-SHP-1 (all purchased from Santa Cruz Biotechnology), and the anti-p85 subunit of phosphatidylinositol 3-kinase antiserum (kindly provided by Dr. Lewis Cantley).
Growth Assay--
BaF3 cells expressing the wild type EpoR or
the EpoR-GFP chimera were washed three times with RPMI and plated at a
density of 5 × 104 cells/well in 24-well plates in
the presence of Epo concentrations ranging from 0.1 to 10 units/ml or
10% WEHI conditioned medium as a source for interleukin-3.
After 3 days, cell numbers were determined using a Coulter counter and
expressed as the percentage of growth obtained in a parallel well
containing 10% WEHI conditioned medium instead of Epo.
Confocal Microscopy--
The localization of GFP-EpoR fusion
proteins and HA-tagged EpoR was assessed in 293T cells transiently
transfected with retroviral expression vector constructs. The cells
were grown on coverslips in six-well plates and either directly
analyzed by immunofluorescence or fixed with 3%
para-formaldehyde for 15 min at room temperature prior to
immunostaining. For co-staining of HA-tagged receptors, the cells were
permeabilized with 0.2% Triton X-100 in phosphate-buffered saline.
After three washes in phosphate-buffered saline, the cells were
incubated with an antibody raised against HA (Roche Molecular Biochemicals). After three washes, the cells were incubated with an
anti-rat IgG coupled to Alexa594 (Molecular Probes, Inc.,
Eugene, OR). All incubations with antibodies were performed
at 4 °C in phosphate-buffered saline supplemented with 0.3% bovine
serum albumin. The antibodies were used as 1:100 dilutions. Fetal liver cells from day 13.5 Balb/c were grown on coverslips precoated with
0.2% gelatin (Sigma) for 20 h in Iscove's modified
Eagle's medium, 30% fetal calf serum supplemented with 0.5 unit/ml
Epo. The cells were washed and analyzed with a Leica DM IRE2 confocal microscope.
 |
RESULTS |
GFP Insertions in the Erythropoietin Receptor--
To visualize
the EpoR and to check whether a visible EpoR is capable of activation
of signal transduction in response to ligand binding, we inserted the
GFP at four positions of the EpoR (Fig. 1). In the resulting chimeric proteins,
GFP is either located at the junction between the extracellular and TM
domains (EpoR-GFP1) or at various positions within the cytoplasmic
domain. In EpoR-GFP2, the insertion of GFP directly after the TM domain
alters the spacing between the hydrophobic juxtamembrane motif and the
JAK2 binding sites, whereas in EpoR-GFP3 the JAK2-activating domain is
separated from the eight cytosolic tyrosine residues that mediate the
recruitment of signaling molecules. The least invasive chimeric
receptor is EpoR-GFP4, where GFP is fused to the C terminus of the
EpoR.

View larger version (29K):
[in this window]
[in a new window]
|
Fig. 1.
EpoR-GFP chimeric proteins. The EpoR is
schematically depicted, and extracellular, cytoplasmic, and TM domains
are indicated. The dark line in the extracellular
domain indicates the WSXWS motif. The striped
boxes in the membrane-proximal portion of the cytoplasmic
domain symbolize box 1 and box 2, where box 1 contains the continuous
block of amino acids required for JAK2 binding. The
horizontal lines in the membrane-distal portion
indicate the eight tyrosine residues. The dark
circle represents GFP that was inserted at the indicated
positions in the EpoR. The numbers mark amino acid positions
in the EpoR, and additionally introduced amino acids are indicated in
single letter code.
|
|
GFP Insertion in the Cytoplasmic Domain Does Not Impair Cell
Surface Expression of the EpoR--
To test the functionality of the
EpoR-GFP receptors, wild type EpoR and chimeric receptors were stable
expressed in the interleukin-3-dependent pro-B cell line
BaF3. Analysis of total cell lysates by immunoblotting with anti-EpoR
antiserum revealed that EpoR-GFP1, EpoR-GFP2, and EpoR-GFP3 were
expressed at levels comparable with wild type EpoR, whereas EpoR-GFP4
reproducibly showed reduced expression levels (Fig.
2A). To evaluate whether GFP
insertion affected surface transport of the chimeric receptors, we
measured 125I-Epo binding to BaF3 cells stable expressing
the EpoR derivatives. As shown in Fig. 2B, chimeric
receptors harboring the GFP insertion in the cytoplasmic domain bound
the ligand to a similar degree as wild type EpoR. It should be noted
that Epo binding to EpoR-GFP2 was reproducibly enhanced. However,
EpoR-GFP1 that contains GFP in the extracellular domain did not show
significant Epo binding. To distinguish whether the lack of Epo binding
was caused by the inability to engage the ligand or by impaired cell
surface expression, we introduced an HA tag in the extracellular domain
of EpoR-GFP1, EpoR-GFP2, and wild type EpoR. Flow cytometry analysis of
BaF3 cells stable expressing the HA-tagged receptors showed that
whereas wild type EpoR and EpoR-GFP2 were detected on the cell surface, EpoR-GFP1 was below the detection limit (Fig. 2C). This
suggests that GFP insertion in the extracellular domain of the EpoR
blocks transport to the cell surface, whereas insertion at various
positions of the cytoplasmic domain does not impair cell surface
prevalence.

View larger version (24K):
[in this window]
[in a new window]
|
Fig. 2.
Cell surface expression of EpoR-GFP chimeric
receptors. A, total cell lysates were prepared
from 2 × 106 BaF3 cells stable expressing GFP, the
EpoR, or EpoR-GFP chimera and analyzed by immunoblotting with anti-EpoR
antiserum. The arrows indicate the position of full-length
EpoR and EpoR-GFP, whereas smaller bands represent cleavage products.
B, saturation binding of 125I-Epo to BaF3 cell
pools stable expressing GFP, the EpoR, or EpoR-GFP chimera. Surface
expression was determined by the extent of 125I-Epo binding
and plotted as specifically bound radioactivity (means ± S.D.,
n = 3). Significance was calculated with a two-sided
paired Student's t test compared with the values of wild
type receptor (**, p < 0.01; ***, p < 0.001). The experiment was repeated three times with comparable
results. C, cell surface expression of HA-tagged EpoR and
EpoR-GFP1 and EpoR-GFP2. BaF3 cells stable expressing HA-EpoR
(blue line), HA-EpoR-GFP1 (green
line), and HA-EpoR-GFP2 (red line)
were incubated with rat anti-HA antiserum followed by Cy5-labeled
anti-rat IgG and analyzed by flow cytometry.
|
|
A Chimeric Receptor Containing GFP in the Middle of the Cytoplasmic
Domain Successfully Coordinates Signaling and Biological
Responses--
To elucidate whether GFP insertion in the cytoplasmic
domain of the EpoR affected the activation of signal transduction,
Epo-induced signaling was studied in BaF3 cells expressing wild type
EpoR or the EpoR-GFP chimera. Tyrosine-phosphorylated JAK2 and EpoR were measured as indicators for Epo-mediated signal transduction (Fig.
3A). Detergent lysates of
cells left untreated or stimulated with Epo were subjected to
immunoprecipitation with anti-EpoR or anti-JAK2 antiserum and
subsequently analyzed by immunoblotting with an anti-phosphotyrosine
monoclonal antibody. As expected, ligand addition to cells expressing
wild type receptor resulted in efficient tyrosine phosphorylation of
the EpoR and JAK2. A receptor chimera that is not transported to the
cell surface (EpoR-GFP1) was unable to trigger tyrosine phosphorylation
of the receptor or JAK2. However, despite its presence on the cell
surface, EpoR-GFP2 was not able to activate signal transduction,
suggesting that structural continuity of the hydrophobic juxtamembrane
domain motif and the JAK2 binding sites is required for efficient
signal conversion. The chimeric receptor EpoR-GFP4 was
tyrosine-phosphorylated upon Epo addition, albeit to a lower extent
than wild type EpoR. This may be due to the reduced expression of this
receptor variant. Surprisingly, a receptor chimera containing the GFP
insertion in the middle of the cytoplasmic domain (EpoR-GFP3) mediated
JAK2 and EpoR tyrosine phosphorylation, indicating that the cytosolic domain of the EpoR is capable of coordinating JAK2 activation and
receptor tyrosine phosphorylation despite physical separation by GFP
insertion. Whereas the unphosphorylated forms of EpoR-GFP3 and
EpoR-GFP4 showed comparable mobility, indicating that GFP insertion had
no major effect, the tyrosine-phosphorylated form of EpoR-GFP3 showed
higher mobility. Therefore, we asked whether this is caused by partial
tyrosine phosphorylation of EpoR-GFP3. The phosphorylation of critical
tyrosine residues in EpoR-GFP3 compared with EpoR-GFP4 was determined
by their capacity to bind the Src homology 2 domain-containing
signaling molecules STAT5, SHP-1, and p85 (Fig. 3B). As
evidenced by immunoprecipitation experiments from detergent lysates of
cells that were left either unstimulated or treated with Epo, both the
tyrosine-phosphorylated forms of EpoR-GFP3 and EpoR-GFP4 were able to
associate with STAT5, SHP1, and p85 comparable with wild type EpoR.
Therefore, both receptor chimera are indistinguishable regarding their
capacity to recruit signaling molecules. It is possible that
underphosphorylation of one of the tyrosine residues to which binding
partners have not yet been identified accounts for the difference in
electrophoretic mobility.

View larger version (31K):
[in this window]
[in a new window]
|
Fig. 3.
Activation of signal transduction by chimeric
receptors harboring GFP inserted in the middle or fused to the C
terminus of the cytoplasmic domain. Starved BaF3 cells expressing
GFP, the EpoR, or EpoR-GFP chimera were left unstimulated ( ) or were
stimulated with Epo (+), lysed, and subjected to immunoprecipitation
(IP) with anti-EpoR and anti-JAK2 antiserum (A)
or anti-STAT5, anti-SHP1, and anti-p85 antiserum (B).
Immunoblotting analysis (IB) was performed using an
anti-phosphotyrosine monoclonal antibody followed by detection with
chemoluminescence. B, the positions of
tyrosine-phosphorylated (pY) EpoR, EpoR-GFP3, EpoR-GFP4,
STAT5, SHP-1, and p85 are indicated by arrows. Equal protein
loading was ensured by reprobing the immunoblots with antibodies
recognizing the respective proteins.
|
|
To test whether the initiation of signal transduction mediated by the
chimeric receptors resulted in efficient biological responses, we first
tested the capacity of the EpoR-GFP receptors to support the growth of
BaF3 cells in the presence of Epo. BaF3 cells expressing either wild
type EpoR or various EpoR-GFP chimeras were cultured in the presence of
increasing concentrations of Epo ranging from 0.1 to 10 Epo units/ml
for 3 days. The cell numbers shown in Fig.
4A indicate that EpoR-GFP3
supported cell proliferation to a similar extent as wild type receptor,
in particular at low Epo concentration, whereas EpoR-GFP4 showed
reduced capacity in promoting proliferation. Confirming the biochemical
analysis, EpoR-GFP chimera that did not activate signal transduction
was unable to support proliferation of BaF3 cells in the presence of
Epo. To further test the biological function of the EpoR-GFP chimera,
the receptors were introduced into fetal liver cells of
EpoR
/
mice by retroviral transduction and tested for
their ability to support the formation of CFU-E colonies in the
presence of Epo. In agreement with the cell proliferation experiments,
EpoR-GFP3 supported similar numbers of CFU-E colonies compared with
wild type EpoR, whereas EpoR-GFP4 reproducibly resulted in a lower number of CFU-E colonies. Again, EpoR-GFP1 and EpoR-GFP2 were unable to
promote proliferation and terminal differentiation of erythroid
progenitor cells. Thus, unexpectedly, an EpoR-GFP receptor containing
GFP inserted in the middle of the cytoplasmic domain was functionally
indistinguishable from the wild type EpoR, whereas direct fusion of GFP
to the C terminus of the EpoR resulted in a receptor with reduced
activity.

View larger version (17K):
[in this window]
[in a new window]
|
Fig. 4.
EpoR-GFP chimeric receptors capable of signal
transduction support proliferation and differentiation.
A, proliferation of parental BaF3 cells or BaF3 cells
expressing the EpoR or EpoR-GFP chimera in response to Epo. Cell
numbers were determined using a Coulter counter. Growth is displayed as
the mean percentage ± S.D. of the cell numbers obtained in WEHI
conditioned medium for three independent cell pools. The experiment was
performed four times with similar results. B, formation of
CFU-E colonies upon expression of the EpoR or EpoR-GFP chimera in fetal
liver cells from EpoR / mice. Transduced fetal liver
cells from EpoR / mice were plated in methylcellulose
supplemented with 4 units/ml Epo. The values plotted (mean ± S.D., n = 3) represent the number of CFU-E colonies
that were counted upon benzidine staining of hemoglobinized cells.
Similar results were obtained in three independent experiments.
Comparable gene transfer rates of the transducing supernatants were
confirmed by measuring GFP expression in transduced wild type fetal
liver cells by flow cytometry.
|
|
In Vivo Localization of the EpoR--
To test whether the EpoR-GFP
chimeras are detectable by fluorescence microscopy and whether
the fluorescence intensity is sufficient to monitor EpoR trafficking in
living cells, we analyzed the chimeric receptors expressed in
transiently transfected 293T cells by confocal microscopy (Fig.
5A). The signaling-competent receptors EpoR-GFP3 and EpoR-GFP4 were detectable in intracellular structures resembling the ER, the Golgi, and punctated endosome-like structures. We performed overlay analysis of EpoR-GFP3 and a
transiently expressed HA-tagged EpoR detected by anti-HA
immunostaining. The HA-tagged EpoR is functionally indistinguishable
from wild type EpoR (21) and showed similar subcellular localization
(data not shown), thus confirming that the enrichment in punctated
structures is not caused by GFP insertion. In erythroid progenitor
cells, accumulation of EpoR-GFP3 in similar punctated structures was observed (Fig. 5B). Expression in other intracellular
compartments was observed but was much dimmer compared with the bright
endosome-like structures. The EpoR-GFP1 chimera that is unable to reach
the cell surface predominantly resides within the ER network, and cells
transfected with EpoR-GFP2, a receptor that is transported to the cell
surface yet unable to trigger the activation of signaling, show
an intermediate phenotype. The EpoR-GFP2 receptor predominantly remains
in the ER, and only a minor portion is enriched in punctated structures.

View larger version (49K):
[in this window]
[in a new window]
|
Fig. 5.
The EpoR localized to endosomal structures in
living cells. Confocal microscopy of GFP-EpoR and HA-EpoR in
transfected 293T cells (A) and in transduced fetal liver
cells (B). The cells were fixed with
para-formaldehyde and permeabilized with 0.2% Triton X-100.
HA-EpoR was detected with a rat antibody raised against HA and a
secondary anti-rat IgG coupled to Alexa594. Transfection efficiencies
were comparable for all constructs. Confocal images were taken 48 h after transient transfection using a Leica DM IRE2 confocal
microscope.
|
|
Our analysis shows that the EpoR-GFP chimeric receptors facilitate the
detection of EpoR and trafficking in living cells and therefore provide
the possibility to visualize dynamic processes in vivo.
 |
DISCUSSION |
Signal conversion through cytokine receptors relies on intricate
communication between the extracellular ligand binding domain and the
cytosolic domain that mediates recruitment of signaling molecules.
Here, we demonstrate that signal transduction via the EpoR, a member of
the cytokine receptor superfamily, can occur despite physical
separation of the JAK2 binding site from the cytosolic tyrosine
residues, which are phosphorylated upon stimulation with Epo.
Insertion of GFP at the junction between the extracellular and TM
domains results in a chimeric receptor not transported to the cell
surface and unable to bind ligand. This phenotype is reminiscent of
mutations in the WSXWS motif in the EpoR extracellular domain, since deletion or alterations in the WSXWS motif
resulted in receptors that were retained in the ER and unable to
interact with the ligand (22). The WSXWS motif is conserved
in the extracellular domain of cytokine receptors and was initially
believed to be involved in ligand binding. However, the crystal
structures of the extracellular domain of the growth hormone receptor
(23) and the EpoR (24) showed that the WSXWS motif is
located away from the interfaces that bind the respective ligand. The
phenotype of the WSXWS mutants rather suggested that the
intact motif is necessary for correct trafficking of the receptor. Our
results indicate that not only the amino acid sequence of the motif but also the spatial localization in close proximity to the cell membrane could be critical for successful transport of the EpoR to the cell surface.
Recent evidence suggests that JAK2 recruitment to the EpoR mediated by
a continuous block of residues in the membrane-proximal segment of the
cytoplasmic domain is required for EpoR cell surface expression (6).
Our analysis of EpoR-GFP2 shows that increasing the distance between
the JAK2 binding motif in the cytoplasmic part of the EpoR and
the cell membrane does not disturb the surface prevalence of
the EpoR. However, physical separation of the JAK2 binding sites from
the precisely oriented hydrophobic motif in the juxtamembrane segment
(5) abrogates the activation of signal transduction. This suggests that
the ligand binding domain, the TM domain, the membrane-proximal
hydrophobic patch, and the JAK2 binding sites are organized in a
structurally rigid entity that requires precise spatial alignment to
activate signal transduction.
The major part of the cytosolic domain encompassing box 2 and the eight
tyrosine residues is contained in exon 8 of the EpoR genomic locus,
suggesting a conserved functional entity. Yet we show that insertion of
GFP in the middle of the cytoplasmic domain results in a chimeric
receptor (EpoR-GFP3) capable of initiating signal transduction and
biological responses comparable with wild type EpoR. The cytoplasmic
domain of the EpoR is partially unfolded in the absence of JAK2 (25),
indicating that JAK2 acts as a molecular chaperone (6) and is required
for structural organization of the cytoplasmic domain. Our results
demonstrate that tyrosine phosphorylation of the cytoplasmic domain is
maintained despite physical separation of the JAK2-activating domain
from the segment harboring the tyrosine residues. This suggests that in
the activated state, JAK2 possesses flexibility in accessing substrate
tyrosine residues and/or that additional JAK2 coordination sites exist in the membrane-distal segment of the EpoR cytoplasmic domain (6). The
possibility that another kinase can compensate for JAK2 is rather
unlikely, since JAK2 null mice show a dramatic phenotype with fetal
anemia and embryonic lethality at day 12.5 comparable with the
EpoR null mice (26, 27).
Previous studies in other receptor systems have been limited to the
analysis of C-terminally GFP-tagged receptors (28, 29). However, the
EpoR that contains GFP fused to the C terminus (EpoR-GFP4) is expressed
at reduced levels and has a decreased capacity to promote the formation
of CFU-E colonies. In this chimeric protein, GFP is localized in close
proximity to Tyr479, a residue that has been shown to be
important for the recruitment of the lipid kinase phosphoinositide
3-kinase (12, 13) and sufficient in the absence of other tyrosine
residues to promote the biological functions of the EpoR (12, 30).
Indeed, further separation of Tyr479 and GFP improved
signal transmission and the capacity to support the biological
functions, although the overall expression levels remained
reduced.2
In summary, we show by marking a hematopoietic cytokine receptor with a
GFP insertion that the extracellular, transmembrane, and
membrane-proximal domains form a rigid structure whose specific orientation is essential for initiating signal transduction in response
to ligand binding. However, we propose that additional coordinating
mechanisms exist, since long range activation of the membrane-distal
part is possible, providing a novel concept how ligand binding is
converted to receptor activation.
 |
ACKNOWLEDGEMENTS |
We thank Susanne Esser and Melanie Wickert
for excellent technical assistance. The anti-p85 antiserum was
generously provided by Lewis C. Cantley, and Stefan Constantinescu
kindly provided the pMX-HA-EpoR-IRES-GFP. We thank Stephan Kuppig for
help with the confocal microscope. We thank Dr. Hong Hu for providing
EpoR knockout mice.
 |
FOOTNOTES |
*
The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
§
Supported by Sonderforschungsbereich SFB364.
¶
Supported by the Boehringer Ingelheim Fonds.
**
Supported by German Israeli Foundation Grant I-666-79.2/2000.

To whom correspondence should be addressed:
Max-Planck-Institute for Immunobiology, Stübeweg 51, 79108 Freiburg, Germany. Fax: 49-761-5108-358; E-mail:
klingmueller@immunbio.mpg.de.
Published, JBC Papers in Press, May 7, 2002, DOI 10.1074/jbc.M202287200
2
R. Ketteler and U. Klingmüller, manuscript
in preparation.
 |
ABBREVIATIONS |
The abbreviations used are:
EpoR, Epo receptor;
STAT, signal transducers and activators of transcription;
GFP, green
fluorescent protein;
HA, hemagglutinin;
TM, transmembrane;
CFU-E, colony-forming unit-erythroid;
ER, endoplasmic reticulum.
 |
REFERENCES |
| 1.
|
Constantinescu, S. N.,
Ghaffari, S.,
and Lodish, H. F.
(1999)
Trends Endocrinol. Metab.
10,
18-23[CrossRef][Medline]
[Order article via Infotrieve]
|
| 2.
|
Klingmüller, U.
(1997)
Eur. J. Biochem.
249,
637-647[Medline]
[Order article via Infotrieve]
|
| 3.
|
Livnah, O.,
Stura, E. A.,
Middleton, S. A.,
Johnson, D. L.,
Jolliffe, L. K.,
and Wilson, I. A.
(1999)
Science
283,
987-990[Abstract/Free Full Text]
|
| 4.
|
Kubatzky, K. F.,
Ruan, W.,
Gurezka, R.,
Cohen, J.,
Ketteler, R.,
Watowich, S. S.,
Neumann, D.,
Langosch, D.,
and Klingmuller, U.
(2001)
Curr. Biol.
11,
110-115[CrossRef][Medline]
[Order article via Infotrieve]
|
| 5.
|
Constantinescu, S. N.,
Huang, L. J.,
Nam, H.,
and Lodish, H. F.
(2001)
Mol. Cell
7,
377-385[CrossRef][Medline]
[Order article via Infotrieve]
|
| 6.
|
Huang, L. J.,
Constantinescu, S. N.,
and Lodish, H. F.
(2001)
Mol. Cell
8,
1327-1338[CrossRef][Medline]
[Order article via Infotrieve]
|
| 7.
|
Nicholson, S. E.,
and Hilton, D. J.
(1998)
J. Leukocyte Biol.
63,
665-668[Abstract]
|
| 8.
|
Klingmüller, U.,
Lorenz, U.,
Cantley, L. C.,
Neel, B. G.,
and Lodish, H. F.
(1995)
Cell
80,
729-738[CrossRef][Medline]
[Order article via Infotrieve]
|
| 9.
|
Myers, M. P.,
Andersen, J. N.,
Cheng, A.,
Tremblay, M. L.,
Horvath, C. M.,
Parisien, J. P.,
Salmeen, A.,
Barford, D.,
and Tonks, N. K.
(2001)
J. Biol. Chem.
276,
47771-47774[Abstract/Free Full Text]
|
| 10.
|
Irie-Sasaki, J.,
Sasaki, T.,
Matsumoto, W.,
Opavsky, A.,
Cheng, M.,
Welstead, G.,
Griffiths, E.,
Krawczyk, C.,
Richardson, C. D.,
Aitken, K.,
Iscove, N.,
Koretzky, G.,
Johnson, P.,
Liu, P.,
Rothstein, D. M.,
and Penninger, J. M.
(2001)
Nature
409,
349-354[CrossRef][Medline]
[Order article via Infotrieve]
|
| 11.
|
Kirito, K.,
Nakajima, K.,
Watanabe, T.,
Uchida, M.,
Tanaka, M.,
Ozawa, K.,
and Komatsu, N.
(2002)
Blood
99,
102-110[Abstract/Free Full Text]
|
| 12.
|
Klingmüller, U., Wu, H.,
Hsiao, J. G.,
Toker, A.,
Duckworth, B. C.,
Cantley, L. C.,
and Lodish, H. F.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
3016-3021[Abstract/Free Full Text]
|
| 13.
|
Damen, J. E.,
Cutler, R. L.,
Jiao, H., Yi, T.,
and Krystal, G.
(1995)
J. Biol. Chem.
270,
23402-23408[Abstract/Free Full Text]
|
| 14.
|
Klingmüller, U.,
Bergelson, S.,
Hsiao, J. G.,
and Lodish, H. F.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
8324-8328[Abstract/Free Full Text]
|
| 15.
|
Kirito, K.,
Uchida, M.,
Yamada, M.,
Miura, Y.,
and Komatsu, N.
(1997)
J. Biol. Chem.
272,
16507-16513[Abstract/Free Full Text]
|
| 16.
|
Kirito, K.,
Uchida, M.,
Takatoku, M.,
Nakajima, K.,
Hirano, T.,
Miura, Y.,
and Komatsu, N.
(1998)
Blood
92,
462-471[Abstract/Free Full Text]
|
| 17.
|
Gobert, S.,
Chretien, S.,
Gouilleux, F.,
Muller, O.,
Pallard, C.,
Dusanter-Fourt, I.,
Groner, B.,
Lacombe, C.,
Gisselbrecht, S.,
and Mayeux, P.
(1996)
EMBO J.
15,
2434-2441[Medline]
[Order article via Infotrieve]
|
| 18.
|
Ketteler, R.,
Glaser, S.,
Sandra, O.,
Martens, U. M.,
and Klingmüller, U.
(2002)
Gene Ther.
9,
477-487[CrossRef][Medline]
[Order article via Infotrieve]
|
| 19.
|
Wu, H.,
Liu, X., R., J.,
and Lodish, H. F.
(1995)
Cell
83,
59-67[CrossRef][Medline]
[Order article via Infotrieve]
|
| 20.
|
Levin, I.,
Cohen, J.,
Supino-Rosin, L.,
Yoshimura, A.,
Watowich, S. S.,
and Neumann, D.
(1998)
FEBS Lett.
427,
164-170[CrossRef][Medline]
[Order article via Infotrieve]
|
| 21.
|
Constantinescu, S. N.,
Keren, T.,
Socolovsky, M.,
Nam, H.,
Henis, Y. I.,
and Lodish, H. F.
(2001)
Proc. Natl. Acad. Sci. U. S. A.
98,
4379-4384[Abstract/Free Full Text]
|
| 22.
|
Yoshimura, A.,
Longmore, G.,
and Lodish, H. F.
(1990)
Nature
348,
647-649[CrossRef][Medline]
[Order article via Infotrieve]
|
| 23.
|
de Vos, A. M.,
Ultsch, M.,
and Kossiakoff, A. A.
(1992)
Science
255,
306-312[Abstract/Free Full Text]
|
| 24.
|
Syed, R. S.,
Reid, S. W., Li, C.,
Cheetham, J. C.,
Aoki, K. H.,
Liu, B.,
Zhan, H.,
Osslund, T. D.,
Chirino, A. J.,
Zhang, J.,
Finer-Moore, J.,
Elliott, S.,
Sitney, K.,
Katz, B. A.,
Matthews, D. J.,
Wendoloski, J. J.,
Egrie, J.,
and Stroud, R. M.
(1998)
Nature
395,
511-515[CrossRef][Medline]
[Order article via Infotrieve]
|
| 25.
|
Remy, I.,
Wilson, I. A.,
and Michnick, S. W.
(1999)
Science
283,
990-993[Abstract/Free Full Text]
|
| 26.
|
Neubauer, H.,
Cumano, A.,
Muller, M., Wu, H.,
Huffstadt, U.,
and Pfeffer, K.
(1998)
Cell
93,
397-409[CrossRef][Medline]
[Order article via Infotrieve]
|
| 27.
|
Parganas, E.,
Wang, D.,
Stravopodis, D.,
Topham, D. J.,
Marine, J. C.,
Teglund, S.,
Vanin, E. F.,
Bodner, S.,
Colamonici, O. R.,
van Deursen, J. M.,
Grosveld, G.,
and Ihle, J. N.
(1998)
Cell
93,
385-395[CrossRef][Medline]
[Order article via Infotrieve]
|
| 28.
|
Silverman, M. A.,
Kaech, S.,
Jareb, M.,
Burack, M. A.,
Vogt, L.,
Sonderegger, P.,
and Banker, G.
(2001)
Proc. Natl. Acad. Sci. U. S. A.
98,
7051-7057[Abstract/Free Full Text]
|
| 29.
|
Wouters, F. S.,
and Bastiaens, P. I.
(1999)
Curr. Biol.
9,
1127-1130[CrossRef][Medline]
[Order article via Infotrieve]
|
| 30.
|
Longmore, G. D.,
You, Y.,
Molden, J.,
Liu, K. D.,
Mikami, A.,
Lai, S. Y.,
Pharr, P.,
and Goldsmith, M. A.
(1998)
Blood
91,
870-878[Abstract/Free Full Text]
|
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
A. C. Heinrich, R. Pelanda, and U. Klingmuller
A mouse model for visualization and conditional mutations in the erythroid lineage
Blood,
August 1, 2004;
104(3):
659 - 666.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Faure, D. F. Barber, S. M. Takahashi, T. Jin, and E. O. Long
Spontaneous Clustering and Tyrosine Phosphorylation of NK Cell Inhibitory Receptor Induced by Ligand Binding
J. Immunol.,
June 15, 2003;
170(12):
6107 - 6114.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Ketteler, C. S. Moghraby, J. G. Hsiao, O. Sandra, H. F. Lodish, and U. Klingmuller
The Cytokine-inducible Scr Homology Domain-containing Protein Negatively Regulates Signaling by Promoting Apoptosis in Erythroid Progenitor Cells
J. Biol. Chem.,
January 17, 2003;
278(4):
2654 - 2660.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.